PE20040584A1 - Nuevos analogos de adenosina - Google Patents

Nuevos analogos de adenosina

Info

Publication number
PE20040584A1
PE20040584A1 PE2003000640A PE2003000640A PE20040584A1 PE 20040584 A1 PE20040584 A1 PE 20040584A1 PE 2003000640 A PE2003000640 A PE 2003000640A PE 2003000640 A PE2003000640 A PE 2003000640A PE 20040584 A1 PE20040584 A1 PE 20040584A1
Authority
PE
Peru
Prior art keywords
alkyl
alkylene
cyclopentan
purin
fluoromethyl
Prior art date
Application number
PE2003000640A
Other languages
English (en)
Inventor
Antony Bigot
Andreas Herling
Siegfried Stengelin
Gerhard Jahne
Michael R Myers
Franz Jakob Hock
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20040584A1 publication Critical patent/PE20040584A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE W ES N, NàO, CH; Q ES CH2, O; R1 ES H, ALQUILO C1-C10, ALILO, 2- METILALILO, ENTRE OTROS; T ES ALQUILO C1-C10, CICLOALQUILO C1-C10, ARIL-(ALQUILENO C1-C10)-, ENTRE OTROS; A ES H, ALQUILO C1-C10, HIDROXI-(ALQUILENO C1-C10)-, ENTRE OTROS; B ES H, ALQUILO C1-C10, HIDROXI-(ALQUILENO C1-C10)-, ENTRE OTROS; X ES (A) o (B); n Y p SON CADA UNO 0-3; Y ES H, ALQUILO C1-C10, ARILO, HETEROCICLILO, ENTRE OTROS; E ES O, S. SON COMPUESTOS PREFERIDOS: (1R,2S,3R,5S)-3-{6-[1-(3-CLOROFENIL-1-IL)-PIRROLIDIN-3(S)-ILAMINO]-PURIN-9-IL}-5-FLUOROMETILCICLOPENTAN-1,2-DIOL Y (1R,2S,3R,5S)-3-{6-[(R)-1-(3-CLOROTIOFEN-2-ILMETIL)-PROPILAMINO]-PURIN-9-IL}-5-FLUOROMETILCICLOPENTAN-1,2-DIOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA PREPARACION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE DIABETES TIPO 2, SINDROME METABOLICO, TRASTORNOS LIPIDICOS O ENFERMEDADES CARDIOVASCULARES
PE2003000640A 2002-06-27 2003-06-25 Nuevos analogos de adenosina PE20040584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02014324A EP1375508A1 (en) 2002-06-27 2002-06-27 N6-substituted adenosine analogues and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
PE20040584A1 true PE20040584A1 (es) 2004-11-03

Family

ID=29716849

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000640A PE20040584A1 (es) 2002-06-27 2003-06-25 Nuevos analogos de adenosina

Country Status (19)

Country Link
EP (2) EP1375508A1 (es)
JP (1) JP2006501178A (es)
KR (1) KR20050014888A (es)
CN (1) CN1671728A (es)
AR (1) AR039697A1 (es)
AU (1) AU2003280141A1 (es)
BR (1) BR0312428A (es)
CA (1) CA2490253A1 (es)
HR (1) HRP20041209A2 (es)
IL (1) IL165934A0 (es)
MA (1) MA27465A1 (es)
MX (1) MXPA04012815A (es)
NO (1) NO20050398L (es)
PE (1) PE20040584A1 (es)
PL (1) PL375197A1 (es)
RU (1) RU2005101872A (es)
TW (1) TW200500376A (es)
WO (1) WO2004003002A1 (es)
ZA (1) ZA200410062B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101268046B (zh) 2005-09-21 2012-07-25 辉瑞有限公司 作为毒蕈碱性受体拮抗剂的碳酰胺衍生物
JP2007153789A (ja) * 2005-12-05 2007-06-21 Mitsui Chemicals Inc 光学活性3−アミノピロリジン誘導体の製造方法
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545645A1 (de) * 1965-12-06 1969-08-21 Boehringer Mannheim Gmbh Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP0983768A1 (en) * 1997-05-23 2000-03-08 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AR039697A1 (es) 2005-03-09
BR0312428A (pt) 2005-04-26
PL375197A1 (en) 2005-11-28
JP2006501178A (ja) 2006-01-12
MXPA04012815A (es) 2005-02-24
EP1375508A1 (en) 2004-01-02
CA2490253A1 (en) 2004-01-08
HRP20041209A2 (en) 2005-08-31
EP1527083A1 (en) 2005-05-04
MA27465A1 (fr) 2005-08-01
KR20050014888A (ko) 2005-02-07
WO2004003002A1 (en) 2004-01-08
ZA200410062B (en) 2008-08-27
IL165934A0 (en) 2006-01-15
CN1671728A (zh) 2005-09-21
TW200500376A (en) 2005-01-01
NO20050398L (no) 2005-01-25
RU2005101872A (ru) 2005-08-10
AU2003280141A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
RU2003132687A (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20060487A1 (es) Derivados de 2-carbamida-4-feniltiazol como moduladores de la actividad de quimioquinas
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
RU2004132204A (ru) Имидазоконденсированные соединения
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
EA200601773A1 (ru) Тетраазабензо[е]азуленовые производные и их аналоги
ATE425166T1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
RU2009135621A (ru) Хинолиновые производные для лечения воспалительных заболеваний
PE20060501A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
PE20060837A1 (es) COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS
AR038864A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
MA27582A1 (fr) Derives benzazepine pour le traitement de troubles neurologiques
EA200600928A1 (ru) Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
AR048282A1 (es) Indol- o - glucosidos sustituidos
AR048376A1 (es) C- glicosidos heterociclos fusionados sustituidos
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
EA200601239A1 (ru) Замещённые хинолиновые соединения
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
AR026024A1 (es) Compuestos inhibidores sglt2 de glucosidos de c-arilo y metodo, las composiciones faramceuticas que los contienen y los intermediarios de sintesis dedichos compuestos

Legal Events

Date Code Title Description
FC Refusal